AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16537575 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin 40 mg/d
Number of subjects: 3648
Study 16537575 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quintile of Lp-PLA2 activity
Number of subjects: 3648
Study 14511278 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine hydrochloride (up to 40 mg per day)
Number of subjects: 31
Study 10883742 — intervention group
Group type: EXPERIMENTAL
Intervention: Levalbuterol 1.25 mg
Number of subjects: 20
Study 10883742 — intervention group
Group type: EXPERIMENTAL
Intervention: Levalbuterol 0.63 mg
Number of subjects: 20
Study 10883742 — intervention group
Group type: COMPARATOR
Intervention: Racemic albuterol 2.50 mg
Number of subjects: 20
Study 10883742 — intervention group
Group type: EXPERIMENTAL
Intervention: Levalbuterol 0.31 mg
Number of subjects: 20
Study 10883742 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9184707 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin plus ticarcillin/clavulanate
Number of subjects: 8
Study 9184707 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin plus ceftazidime
Number of subjects: 8
Study 9184707 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin plus placebo
Number of subjects: 8
Study 9184707 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin plus piperacillin
Number of subjects: 8
Study 1383107 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVD plus radiotherapy
Number of subjects: 0
Study 1383107 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 0
Study 2857103 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 22
Study 2857103 — intervention group
Group type: COMPARATOR
Intervention: Vasopressin
Number of subjects: 22
Study 29716436 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine Tablets 3.5 mg/kg
Number of subjects: 0
Study 29716436 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29227155 — intervention group
Group type: EXPERIMENTAL
Intervention: FANS (family and friends network support), a text message support curriculum synchronized to patient messages
Number of subjects: 44
Study 26969299 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive remediation protocol
Number of subjects: 100
Study 26969299 — intervention group
Group type: COMPARATOR
Intervention: Active computer control
Number of subjects: 100
Study 25142773 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP pressure
Number of subjects: 78
Study 25142773 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP pressure cutoff of 13 cm H2O
Number of subjects: 78
Study 25142773 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP pressure, age, and AHI
Number of subjects: 78
Study 22949276 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver problem-solving intervention (CPSI)
Number of subjects: 255
Study 22949276 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (WLC)
Number of subjects: 255
Study 20205647 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-steroidal anti-inflammatory drugs (NSAIDs)
Number of subjects: 0
Study 17646272 — intervention group
Group type: EXPERIMENTAL
Intervention: SOD2 Ala variant (Ex2+24T>C)
Number of subjects: 3200
Study 17646272 — intervention group
Group type: EXPERIMENTAL
Intervention: SOD2 Ala allele carriers with lower vitamin E intake (</=222 IU/d)
Number of subjects: 3200
Study 17646272 — intervention group
Group type: EXPERIMENTAL
Intervention: SOD2 Ala allele carriers with higher vitamin E intake (>222 IU/d)
Number of subjects: 3200
Study 17646272 — intervention group
Group type: COMPARATOR
Intervention: SOD3 and SOD1 polymorphic variants
Number of subjects: 3200
Study 16203930 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents
Number of subjects: 160
Study 16203930 — intervention group
Group type: COMPARATOR
Intervention: Standard stents
Number of subjects: 160
Study 12390315 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal and Haemophilus influenzae type b vaccines
Number of subjects: 93
Study 12390315 — intervention group
Group type: COMPARATOR
Intervention: High activity antiretroviral treatment (HAART)
Number of subjects: 93
Study 10426173 — intervention group
Group type: EXPERIMENTAL
Intervention: RRV-TV vaccine
Number of subjects: 249
Study 10426173 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 249
Study 7776542 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 RI (reinjection at 24 hours later with 37 MBq of thallium‐201)
Number of subjects: 45
Study 7776542 — intervention group
Group type: COMPARATOR
Intervention: 24 DL (24 hours delayed imaging)
Number of subjects: 45
Study 2184945 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise regimen (walking, jogging, stationary bicycling) for 30 minutes, four times a week at 65-80% maximal heart rate
Number of subjects: 27
Study 2184945 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover to aerobic regimen after control
Number of subjects: 27
Study 2184945 — intervention group
Group type: COMPARATOR
Intervention: Control regimen (slow calisthenics and stretching) for 30 minutes, four times a week at less than 60% maximal heart rate
Number of subjects: 27
Study 7347118 — intervention group
Group type: EXPERIMENTAL
Intervention: Ioxaglate (Hexabrix)
Number of subjects: 52
Study 7347118 — intervention group
Group type: COMPARATOR
Intervention: Conventional monomeric contrast media
Number of subjects: 52
Study 31706541 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous platelet-rich gel (APG)
Number of subjects: 48
Study 31706541 — intervention group
Group type: COMPARATOR
Intervention: Conventional wound dressing
Number of subjects: 48
Study 30737333 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod
Number of subjects: 589
Study 30737333 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon [IFN]‐β‐1a
Number of subjects: 589
Study 30737333 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 589
Study 30737333 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with high baseline NfL levels
Number of subjects: 589
Study 28623597 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative treatment
Number of subjects: 69
Study 28623597 — intervention group
Group type: COMPARATOR
Intervention: Surgical treatment
Number of subjects: 69
Study 25482466 — intervention group
Group type: EXPERIMENTAL
Intervention: udenafil (50 mg) for 12 weeks
Number of subjects: 80
Study 25482466 — intervention group
Group type: COMPARATOR
Intervention: placebo (50 mg) for 12 weeks
Number of subjects: 80
Study 23625275 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation (CA) for atrial fibrillation (AF)
Number of subjects: 35
Study 21483008 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision Aid (DA) - take-home booklet with audio recording, reviewed by an oncologist
Number of subjects: 207
Study 21483008 — intervention group
Group type: COMPARATOR
Intervention: Standard medical oncology consultation
Number of subjects: 207
Study 18777127 — intervention group
Group type: EXPERIMENTAL
Intervention: Suture ligation
Number of subjects: 124
Study 18777127 — intervention group
Group type: COMPARATOR
Intervention: Radiowave ablation
Number of subjects: 124
Study 16703596 — intervention group
Group type: EXPERIMENTAL
Intervention: GST-M1 null genotype
Number of subjects: 303
Study 16703596 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous nonnull status for both GST genotypes
Number of subjects: 303
Study 16703596 — intervention group
Group type: EXPERIMENTAL
Intervention: GST-T1 null genotype and bleomycin-induced chromatid breaks
Number of subjects: 303
Study 14996880 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular injection of hyaluronic acid
Number of subjects: 20
Study 14996880 — intervention group
Group type: COMPARATOR
Intervention: Intra-articular injection of placebo
Number of subjects: 20
Study 11296435 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 2 micrograms.kg-1
Number of subjects: 45
Study 11296435 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 4 micrograms.kg-1
Number of subjects: 45
Study 11296435 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 45
Study 9382907 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 0.3 mg/kg twice daily
Number of subjects: 125
Study 9382907 — intervention group
Group type: COMPARATOR
Intervention: Dexamphetamine (DEX) 0.15 mg/kg twice daily
Number of subjects: 125
Study 9382907 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 125
Study 9382907 — intervention group
Group type: COMPARATOR
Intervention: Dexamphetamine (DEX)
Number of subjects: 125
Study 9382907 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Performance Test
Number of subjects: 125
Study 8195450 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (low dose: 0.5 mg/kg per day)
Number of subjects: 0
Study 8195450 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (medium dose: 1.5 mg/kg per day)
Number of subjects: 0
Study 8195450 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (high dose: 3.0 mg/kg per day)
Number of subjects: 0
Study 8195450 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (all doses)
Number of subjects: 0
Study 8195450 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (high dose)
Number of subjects: 0
Study 8195450 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2895838 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 217
Study 2895838 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 217
Study 31579909 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm A (common protocol)
Number of subjects: 411
Study 31579909 — intervention group
Group type: COMPARATOR
Intervention: Arm B (local protocol)
Number of subjects: 411
Study 31579909 — intervention group
Group type: COMPARATOR
Intervention: Arm C (local protocol)
Number of subjects: 411
Study 31579909 — intervention group
Group type: COMPARATOR
Intervention: Arm D (local protocol)
Number of subjects: 411
Study 31579909 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm C (Trial 2)
Number of subjects: 411
Study 29846843 — intervention group
Group type: EXPERIMENTAL
Intervention: Velmanase alfa (VA) 1 mg/kg weekly for 52 weeks
Number of subjects: 25
Study 29846843 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 29846843 — intervention group
Group type: COMPARATOR
Intervention: Placebo (after switch to VA)
Number of subjects: 25
Study 27277262 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education intervention consisting of six classroom sessions and home visits by trained community health workers.
Number of subjects: 72
Study 27277262 — intervention group
Group type: COMPARATOR
Intervention: Usual care plus printed educational materials (Control group).
Number of subjects: 72
Study 24733910 — intervention group
Group type: EXPERIMENTAL
Intervention: PROSTVAC-VF vaccine
Number of subjects: 100
Study 24733910 — intervention group
Group type: EXPERIMENTAL
Intervention: PROSTVAC-VF combined with Quadramet
Number of subjects: 100
Study 24733910 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 100
Study 23362251 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Dolphinarium intervention
Number of subjects: 0
Study 23362251 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilot study for autism screening
Number of subjects: 0
Study 20840692 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-layer closure of the uterine incision
Number of subjects: 3033
Study 20840692 — intervention group
Group type: COMPARATOR
Intervention: Double-layer closure of the uterine incision
Number of subjects: 3033
Study 20840692 — intervention group
Group type: EXPERIMENTAL
Intervention: Closure of the pelvic peritoneum
Number of subjects: 3033
Study 20840692 — intervention group
Group type: COMPARATOR
Intervention: Nonclosure of the pelvic peritoneum
Number of subjects: 3033
Study 20840692 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal use of a subrectus sheath drain
Number of subjects: 3033
Study 20840692 — intervention group
Group type: COMPARATOR
Intervention: Restricted use of a subrectus sheath drain
Number of subjects: 3033
Study 18837867 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRI
Number of subjects: 344
Study 18837867 — intervention group
Group type: EXPERIMENTAL
Intervention: IPT
Number of subjects: 344
Study 18837867 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 344
Study 17181436 — intervention group
Group type: EXPERIMENTAL
Intervention: Pollinex® Quattro (allergy vaccine)
Number of subjects: 0
Study 10853311 — intervention group
Group type: EXPERIMENTAL
Intervention: OCT examination of symptom-free fellow eyes with a foveal cyst
Number of subjects: 66
Study 10853311 — intervention group
Group type: COMPARATOR
Intervention: OCT examination of symptom-free fellow eyes without a foveal cyst
Number of subjects: 66
Study 9376452 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance nortriptyline
Number of subjects: 0
Study 9376452 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8411909 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine (20mg administered intravenously immediately after the operation and twice daily from postoperative day 1 until day 7)
Number of subjects: 21
Study 8411909 — intervention group
Group type: COMPARATOR
Intervention: Control group (11 cases)
Number of subjects: 21
Study 3536890 — intervention group
Group type: EXPERIMENTAL
Intervention: Limbitrol
Number of subjects: 0
Study 3536890 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 0
Study 31779001 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFA supplementation (5 g/day of fish oil providing 1.9-2.2 g of eicosapentaenoic acid + 1.1 g of docosahexaenoic acid)
Number of subjects: 210
Study 31779001 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic Risk Score (GRS) based on genome-wide association analysis
Number of subjects: 210
Study 29460817 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil liquid softgel (Ocean plus®)
Number of subjects: 120
Study 29460817 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sunflower oil liquid softgel)
Number of subjects: 120
Study 27539053 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone followed by oxytocin
Number of subjects: 135
Study 27539053 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 135
Study 27539053 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 135
Study 25148234 — intervention group
Group type: EXPERIMENTAL
Intervention: Metreleptin
Number of subjects: 18
Study 25148234 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 20677841 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulations designed to challenge smoking-related outcome expectancies for pain reduction
Number of subjects: 132
Study 20677841 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulations designed to enhance pain-related coping
Number of subjects: 132
Study 20677841 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of both manipulations
Number of subjects: 132
Study 20677841 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 132
Study 18684437 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruminative self-focus
Number of subjects: 0
Study 18684437 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative life events
Number of subjects: 0
Study 18684437 — intervention group
Group type: EXPERIMENTAL
Intervention: Momentary ruminative self-focus
Number of subjects: 0
Study 18684437 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms
Number of subjects: 0
Study 18684437 — intervention group
Group type: EXPERIMENTAL
Intervention: Trait rumination
Number of subjects: 0
Study 16320099 — intervention group
Group type: EXPERIMENTAL
Intervention: Talampanel (TLP) 75 mg single oral dose
Number of subjects: 28
Study 12439210 — intervention group
Group type: COMPARATOR
Intervention: Vitamin A supplementation (not randomized)
Number of subjects: 1078
Study 12439210 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 1078
Study 12439210 — intervention group
Group type: EXPERIMENTAL
Intervention: High maternal viral load
Number of subjects: 1078
Study 12439210 — intervention group
Group type: EXPERIMENTAL
Intervention: Low CD4 cell count
Number of subjects: 1078
Study 12439210 — intervention group
Group type: EXPERIMENTAL
Intervention: High maternal erythrocyte sedimentation rate (ESR)
Number of subjects: 1078
Study 12439210 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast lesions during pregnancy
Number of subjects: 1078
Study 10450459 — intervention group
Group type: EXPERIMENTAL
Intervention: Vignette only
Number of subjects: 0
Study 10450459 — intervention group
Group type: EXPERIMENTAL
Intervention: Vignette plus two options
Number of subjects: 0
Study 10450459 — intervention group
Group type: EXPERIMENTAL
Intervention: Vignette plus the same two options with one positive and one negative consequence
Number of subjects: 0
Study 8601999 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbitone
Number of subjects: 167
Study 8601999 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 167
Study 8601999 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 167
Study 8601999 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Valproate
Number of subjects: 167
Study 8601999 — intervention group
Group type: COMPARATOR
Intervention: All drugs
Number of subjects: 167
Study 1934379 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral isosorbide dinitrate (ISDN) Q 4 hours
Number of subjects: 44
Study 1934379 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral isosorbide dinitrate (ISDN) Q 6 hours
Number of subjects: 44
Study 1934379 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral isosorbide dinitrate (ISDN) Q 8 hours
Number of subjects: 44
Study 1934379 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral isosorbide dinitrate (ISDN) t.i.d. (0, 6, 12, and 24 hours)
Number of subjects: 44
Study 6462116 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen sodium 550 mg twice daily
Number of subjects: 37
Study 6462116 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal 500 mg twice daily
Number of subjects: 37
Study 6462116 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 30821614 — intervention group
Group type: EXPERIMENTAL
Intervention: Supporting Father Involvement couples group intervention
Number of subjects: 239
Study 29931434 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedtime Fading with Response Cost (BFRC)
Number of subjects: 3
Study 27574287 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting glucose (quartile 3 vs. quartile 1)
Number of subjects: 1035
Study 27574287 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting glucose (quartile 4 vs. quartile 1)
Number of subjects: 1035
Study 27574287 — intervention group
Group type: EXPERIMENTAL
Intervention: Undiagnosed diabetes
Number of subjects: 1035
Study 27574287 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum insulin (quartile 4 vs. quartile 1)
Number of subjects: 1035
Study 27574287 — intervention group
Group type: EXPERIMENTAL
Intervention: HOMA-IR (quartile 4 vs. quartile 1)
Number of subjects: 1035
Study 27574287 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum insulin (CLD)
Number of subjects: 1035
Study 27574287 — intervention group
Group type: EXPERIMENTAL
Intervention: HOMA-IR (CLD)
Number of subjects: 1035
Study 25054436 — intervention group
Group type: EXPERIMENTAL
Intervention: Colesevelam 3.8 g/day
Number of subjects: 562
Study 25054436 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 562
Study 22727707 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4mg/day)
Number of subjects: 19
Study 22727707 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 19395357 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel computer‐administered measure for malingering detection
Number of subjects: 114
Study 19395357 — intervention group
Group type: EXPERIMENTAL
Intervention: Total completion time and learning curves as genuine impairment indicators
Number of subjects: 114
Study 17470380 — intervention group
Group type: EXPERIMENTAL
Intervention: Taribavirin 800 mg QD
Number of subjects: 180
Study 17470380 — intervention group
Group type: EXPERIMENTAL
Intervention: Taribavirin 1200 mg QD
Number of subjects: 180
Study 17470380 — intervention group
Group type: EXPERIMENTAL
Intervention: Taribavirin 1600 mg QD
Number of subjects: 180
Study 17470380 — intervention group
Group type: COMPARATOR
Intervention: Ribavirin 1000 mg QD
Number of subjects: 180
Study 17470380 — intervention group
Group type: COMPARATOR
Intervention: Ribavirin 1200 mg QD
Number of subjects: 180
Study 17470380 — intervention group
Group type: EXPERIMENTAL
Intervention: Taribavirin (any dose)
Number of subjects: 180
Study 17470380 — intervention group
Group type: COMPARATOR
Intervention: Ribavirin (any dose)
Number of subjects: 180
Study 17470380 — intervention group
Group type: EXPERIMENTAL
Intervention: Taribavirin
Number of subjects: 180
Study 17470380 — intervention group
Group type: COMPARATOR
Intervention: Ribavirin
Number of subjects: 180
Study 15184351 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin combined with ramipril
Number of subjects: 95
Study 15184351 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin alone
Number of subjects: 95
Study 15184351 — intervention group
Group type: COMPARATOR
Intervention: Ramipril alone
Number of subjects: 95
Study 15184351 — intervention group
Group type: COMPARATOR
Intervention: Ramipril alone or simvastatin combined with ramipril
Number of subjects: 95
Study 12100225 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine 5 mg
Number of subjects: 19
Study 12100225 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 12100225 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine 50 mg
Number of subjects: 19
Study 9676028 — intervention group
Group type: EXPERIMENTAL
Intervention: AML-type chemotherapy
Number of subjects: 0
Study 9676028 — intervention group
Group type: COMPARATOR
Intervention: Clinical trials participation
Number of subjects: 0
Study 8618802 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct FT4 assay screening for hypothyroidism
Number of subjects: 235